Dendreon is a biotechnology company focused on targeting cancer and transforming lives through discovering, developing, commercializing and manufacturing novel therapeutics. Dendreon utilizes its antigen identification, engineering and cell processing expertise to produce active cellular immunotherapy (ACI) product candidates that are designed to stimulate an immune response in various tumor types. PROVENGE (sipuleucel-T), the company’s first product, received FDA approval in April 2010. For more information, visit the company’s Web site: http://www.dendreon.com
Let us hear your thoughts below: